Provider of skin cancer screening services designed to detect and manage skin cancer risk. DermaScan is based in Paris, France. Its last reported valuation was $950,000 in Dec 2024. It has raised $2.8 million.
Last reported valuation
$950K
Oct 2026
Priced at
—
Total raised
$2.8M
Last round
—
Cap table — not yet on record
DermaScan's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of DermaScan with a free account
·Watch DermaScan: the Monday email on marks, rounds and moves
